GW Pharmaceuticals — FY2020 Earnings Presentation
10 slides from GW Pharmaceuticals's earnings presentation, Feb 23, 2021
Slide 1: 2020 Fourth Quarter and Full Year Financial Results
2020 fourth Quarter and full year Financial Results INNOVATING TO TRANSFORM THE LIVES OF PATIENTS February 23, 2021 © 2020 Jazz Pharmaceuticals all rights reserved.
Slide 2: Forward-Looking Statements Safe Harbor Statement
Life-Changing Medicines. Redefining Possibilities. Forward-Looking Statements “Safe Harbor" Statement Under The Private Securities Litigation Reform Act of 1995 This communication contain forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals’ future fi
Slide 3: Forward-Looking Statements (Continued)
Life-Changing Medicines. Redefining Possibilities. Forward-Looking Statements “Safe Harbor" Statement Under The Private Securities Litigation Reform Act of 1995 (Continued from Previous Slide) obtaining and maintaining adequate coverage and reimbursement for the company’s products; identifying and a
Slide 4: Non-GAAP Financial Measures
Life-Changing Medicines. Redefining Possibilities. Non-GAAP Financial Measures To supplement Jazz Pharmaceuticals’ financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), the company uses certain non-GAAP (also referred to as adjusted or non-
Slide 5: Important Information About the Proposed Transaction
February 2021 In connection with the proposed transaction, GW Pharmaceuticals intends to file a proxy statement with the SEC. Each of Jazz Pharmaceuticals and GW Pharmaceuticals may also file other relevant documents with the SEC regarding the proposed transaction. The definitive proxy statement (if
Slide 6: Transaction Overview: GW Pharmaceuticals PLC
Transaction Overview: GW Pharmaceuticals PLC
Slide 7: GW Acquisition Expected to Drive Substantial Shareholder Value
GW Acquisition Expected to Drive Substantial Shareholder Value Creates an innovative, global, high-growth biopharma leader with a robust pipeline and one patient-centric mission Epidiolex has near-term blockbuster potential Combined Neuroscience business has global commercial and operational footpri
Slide 8: Combination Creates Global Neuroscience Leader
Combination Creates Global Neuroscience Leader EPILEPSIES #1 Sleep Disorders Franchise Unparalleled Leader in Cannabinoid Science SLEEP DISORDERS ONCOLOGY Global leaders in complementary areas Addition of third high-growth commercial franchise with blockbuster potential Highly complementary commerci
Slide 9: Disciplined Allocation of Capital in Alignment With Strategic Priorities
1 Jazz unaudited cash and investments at December 31, 2020. 2 Assumes aggregate transaction value of $7.2B including $6.5B in cash, financed by cash on hand and new debt, and $0.7B in Jazz shares. 3 By the end of 2022 Leveraging financial strength Transaction Aligned to capital allocation strategy D
Slide 10: Purchase Price, Financial Impact, Funding and Approvals
Purchase Price Holders of GW ADSs, which each represent 12 GW ordinary shares, will be entitled to receive $220 for each GW ADS Representing $200 in cash and $20 in shares of Jazz stock, subject to a 10% collar centered on Jazz’s closing share price on February 1, 2021 Total transaction enterprise v